Clinical features and treatment of hematopoietic stem cell transplantation-associated gastric antral vascular ectasia.
Gastric antral vascular ectasia (GAVE) may occur after hematopoietic stem cell transplantation (HSCT) and cause severe and prolonged gastric bleeding. The underlying pathology of transplant-associated GAVE (HSCT-GAVE) is poorly understood and an effective therapeutic strategy has not been established yet. We retrospectively reviewed the medical records of 230 consecutive allogeneic transplant recipients in our institution between January 1997 and June 2002. We identified five patients who developed HSCT-GAVE (2.2%). Four patients had bleeding from HSCT-GAVE and one patient had HSCT-GAVE discovered incidentally. The clinical features of these patients were similar in that they all received conditioning treatment with busulfan and had history of thrombotic microangiopathy. Furthermore, treatment with a beta-blocker apparently improved the outcome of HSCT-GAVE in three patients.
Ohashi
K
K
1Hematology Division, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Sanaka
M
M
Tu
Y
Y
Egawa
N
N
Ohashi
K
K
Funata
N
N
Okuyama
Y
Y
Hiruma
K
K
Tanaka
Y
Y
Mori
S
S
Akiyama
H
H
Sakamaki
H
H
D000293:Adolescent; D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001706:Biopsy; D002066:Busulfan / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000473:pathology; D005260:Female; D020252:Gastric Antral Vascular Ectasia / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy; D012189:Retrospective Studies; D013997:Time Factors; D019172:Transplantation Conditioning
D018906:Antineoplastic Agents, Alkylating; D007166:Immunosuppressive Agents; D002066:Busulfan